It’s common to start a new year with bold ambitions, but where is the industry really setting its sights for the year ahead, have organisations pitched their plans appropriately for this fast-changing market, and how much of the agenda is – and should be – AI-oriented?
Looking across late-stage pharma R&D, three dominant themes emerge for 2026. These reflect a maturing AI landscape, regulatory pressures driving digital transformation and fundamental shifts in how life sciences organisations must organise work and data.
These themes come together, or ought to, in the context of providing a better experience for patients.
Check out the rest of the feature here
